Prescient Therapeutics Limited (ASX:PTX)

Market Cap	51.52M
Revenue (ttm)	4.36M
Net Income (ttm)	-7.32M
Shares Out	1.05B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	651,812
Average Volume	1,154,280
Open	0.0510
Previous Close	0.0500
Day's Range	0.0480 - 0.0510
52-Week Range	0.0370 - 0.0630
Beta	0.35
RSI	62.33
Earnings Date	Nov 19, 2025

About Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PTX

Financial Performance

In 2025, Prescient Therapeutics's revenue was 4.36 million, an increase of 17.35% compared to the previous year's 3.71 million. Losses were -7.32 million, -11.11% less than in 2024.